Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,234.00    80.00 (0.61%)
Bid:
13,216.00
Ask:
13,220.00
Spread: 4.00 (0.03%)
Market Cap: £205.24b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Form 8.5 (EPT/RI) Replacement Pfizer Inc

21 May 2014 17:23

RNS Number : 7479H
Morgan Stanley & Co. Int'l plc
21 May 2014
 



AMENDMENT

 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley & Co. International plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PFIZER INC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

19 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 ADRS

 PURCHASES

 152.00 (Traded in ADR form)

 21.4100 EUR

 21.4100 EUR

 ADRS

 SALES

 27.00 (Traded in ADR form)

 21.4600 EUR

 21.4600 EUR

 COMMON STOCK

 PURCHASES

 385

 21.4450 EUR

 21.4200 EUR

 COMMON STOCK

 SALES

 1,945

 21.7450 EUR

 21.4700 EUR

COMMON STOCK

 PURCHASES

 229

 194.0000 SEK

 193.5000 SEK

COMMON STOCK

 SALES

 229

 195.0000 SEK

 194.0000 SEK

 COMMON STOCK

 PURCHASES

 1,394,641

 29.7750 USD

 29.2800 USD

 COMMON STOCK

 SALES

 399,946

 29.7750 USD

 29.1200 USD

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

21 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERABMFTMBTTBBI
Date   Source Headline
15th Jun 20267:00 amRNSTruqap approved in US for prostate cancer
1st Jun 20263:05 pmRNSAdmission of Further Securities to Trading
1st Jun 20263:00 pmRNSTotal Voting Rights
29th May 20267:00 amRNSImfinzi approved in US for early bladder cancer
27th May 20267:00 amRNSUS FDA decision date on camizestrant extended
26th May 20267:00 amRNSEnhertu recommended in EU for HER2+ solid tumours
26th May 20267:00 amRNSCamizestrant recommended for breast cancer in EU
26th May 20267:00 amRNSDatroway approved in US for 1L triple-negative BC
18th May 20263:00 pmRNSDirector/PDMR Shareholding
18th May 20267:05 amRNSEnhertu approved in two HER2+ early BC settings
18th May 20267:00 amRNSBaxfendy approved in the US for hypertension
14th May 20267:00 amRNSImfinzi + EV improves EFS & OS in bladder cancer
1st May 20263:00 pmRNSTotal Voting Rights and Admission of Shares
1st May 20267:05 amRNSFDA ODAC vote on camizestrant in breast cancer
1st May 20267:00 amRNSFDA ODAC recommends Truqap in prostate cancer
29th Apr 20267:00 amRNS1st Quarter Results
28th Apr 20267:00 amRNSBreztri approved in the US for asthma
27th Apr 20267:00 amRNSSaphnelo self-administration approved in the US
23rd Apr 20267:00 amRNSDirectorate change
21st Apr 20267:00 amRNSI CAN PhIII interim analysis met primary endpoint
20th Apr 20267:00 amRNSThird tozorakimab positive Phase III in COPD
9th Apr 20265:15 pmRNSResult of AGM
2nd Apr 20267:00 amRNSImfinzi+Imjudo improves PFS in early liver cancer
1st Apr 20263:00 pmRNSTotal Voting Rights and Admission of Shares
31st Mar 20267:00 amRNSEfzimfotase alfa Ph3 program show positive results
27th Mar 20267:00 amRNSTozorakimab met OBERON/TITANIA primary endpoints
20th Mar 202611:00 amRNSNotification of Admission of Shares
16th Mar 20267:00 amRNSImfinzi approved in EU for early gastric cancer
16th Mar 20267:00 amRNSImfinzi approved in EU for early gastric cancer
10th Mar 202611:00 amRNSNotice of AGM
10th Mar 202611:00 amRNSNotice of AGM
6th Mar 202611:10 amRNSDirector/PDMR Shareholding
6th Mar 202611:05 amRNSDirector/PDMR Shareholding
6th Mar 202611:00 amRNSDirector/PDMR Shareholding
2nd Mar 20263:00 pmRNSTotal Voting Rights
26th Feb 20267:00 amRNSAstraZeneca prices a $2bn bond offering
25th Feb 20267:00 amRNSFiling of Form 20-F with SEC
24th Feb 202611:00 amRNSAnnual Financial Report
24th Feb 20267:00 amRNSDirectorate change
20th Feb 20267:00 amRNSFixed-duration Calquence combo approved in US
10th Feb 20267:00 amRNSFinal Results
3rd Feb 20267:00 amRNSUpdate on Saphnelo subcutaneous administration
2nd Feb 20263:00 pmRNSTotal Voting Rights
2nd Feb 20267:05 amRNSImfinzi recommended in EU for early gastric cancer
2nd Feb 20267:00 amRNSAstraZeneca begins trading on NYSE
30th Jan 20267:00 amRNSAstraZeneca agrees obesity and T2D deal with CSPC
29th Jan 20269:51 amRNSAstraZeneca invests $15bn in China through 2030
20th Jan 20267:00 amRNSAstraZeneca to complete direct listing on NYSE
8th Jan 20267:00 amRNSAZN new Head of Investor Relations Joris Silon
2nd Jan 20263:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.